Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Future Oncology (London, England)
|
June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Thomas J Herzog, John L Hays, Joyce N Barlin, et al.
JAMA Oncology
|
November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Current Oncology (Toronto, Ont.)
|
June 25, 2026
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer
Kim Ma, Basile Tessier-Cloutier, Alon D Altman, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma
James T Topham, Haley M Beckmann, Joanna M Karasinska, et al.
Nature Medicine
|
March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Ramez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
The New England Journal of Medicine
|
March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Current Oncology (Toronto, Ont.)
|
June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Future Oncology (London, England)
|
June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Thomas J Herzog, John L Hays, Joyce N Barlin, et al.
JAMA Oncology
|
November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Current Oncology (Toronto, Ont.)
|
June 25, 2026
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer
Kim Ma, Basile Tessier-Cloutier, Alon D Altman, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma
James T Topham, Haley M Beckmann, Joanna M Karasinska, et al.
Nature Medicine
|
March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Ramez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
The New England Journal of Medicine
|
March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Current Oncology (Toronto, Ont.)
|
June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Page
of 8